286 related articles for article (PubMed ID: 12113100)
1. Raloxifene for the treatment and prevention of breast cancer?
Pappas SG; Jordan VC
Expert Rev Anticancer Ther; 2001 Oct; 1(3):334-40. PubMed ID: 12113100
[TBL] [Abstract][Full Text] [Related]
2. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
4. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
5. [Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology].
Terán Dávila J; Teppa Garrán AD
Ginecol Obstet Mex; 2005 Aug; 73(8):424-35. PubMed ID: 16304968
[TBL] [Abstract][Full Text] [Related]
6. [Selective estrogen-receptor modulators (SERM's) in postmenopausal women].
Hart W; Netelenbos JC
Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1771-6. PubMed ID: 10494328
[TBL] [Abstract][Full Text] [Related]
7. [Effects of SERMs on bone health. Raloxifene effects on breast cancer and cardiovascular events].
Inoue D
Clin Calcium; 2010 Mar; 20(3):331-8. PubMed ID: 20190362
[TBL] [Abstract][Full Text] [Related]
8. [Clinical experience with raloxifene].
Szúcs J; Pávó I; Jurida N
Orv Hetil; 2000 Jan; 141(5):237-40. PubMed ID: 10697982
[TBL] [Abstract][Full Text] [Related]
9. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
Lee WL; Cheng MH; Chao HT; Wang PH
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
[TBL] [Abstract][Full Text] [Related]
10. Experts hopeful about designer estrogens. For some women, selective estrogen receptor modulators (SERMs) help prevent breast cancer.
Runowicz CD
Health News; 2003 Apr; 9(4):1-2. PubMed ID: 12710388
[No Abstract] [Full Text] [Related]
11. Raloxifene and its role in breast cancer prevention.
Eng-Wong J; Zujewski JA
Expert Rev Anticancer Ther; 2004 Aug; 4(4):523-32. PubMed ID: 15270657
[TBL] [Abstract][Full Text] [Related]
12. [Selective estrogen receptor modulators (SERMs)].
Matsumoto T
Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
[TBL] [Abstract][Full Text] [Related]
13. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
Higuchi T; Mizunuma H
Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
[TBL] [Abstract][Full Text] [Related]
14. [Raloxifene (Celvista, Evista)].
Body JJ; Sternon J
Rev Med Brux; 2000 Feb; 21(1):35-41. PubMed ID: 10748686
[TBL] [Abstract][Full Text] [Related]
15. Raloxifene use in clinical practice: efficacy and safety.
Goldstein SR; Duvernoy CS; Calaf J; Adachi JD; Mershon JL; Dowsett SA; Agnusdei D; Stuenkel CA
Menopause; 2009; 16(2):413-21. PubMed ID: 19092711
[TBL] [Abstract][Full Text] [Related]
16. Selective estrogen receptor modulators and postmenopausal health.
Roe EB; Chiu KM; Arnaud CD
Adv Intern Med; 2000; 45():259-78. PubMed ID: 10635051
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene: bone and cardiovascular effects.
Francucci CM; Romagni P; Boscaro M
J Endocrinol Invest; 2005; 28(10 Suppl):85-9. PubMed ID: 16550730
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of raloxifene: the arterial and venous systems.
Blumenthal RS; Baranowski B; Dowsett SA
Am Heart J; 2004 May; 147(5):783-9. PubMed ID: 15131531
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
Med Lett Drugs Ther; 2006 May; 48(1234):37. PubMed ID: 16685245
[TBL] [Abstract][Full Text] [Related]
20. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
Kastelan D; Korsić M
Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
